By Turna Ray

This article has been updated to clarify comments made by Scientia Advisors' Patrick Terry.

BETHESDA, Md. — As far as XDx is concerned, it has jumped through all the right hoops to show the clinical utility of its AlloMap genomic heart transplant rejection test. But according to a company official, it hasn't seen the level of adoption it expected for the test because doctors don't have a monetary incentive to use it in place of cardiac biopsies.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Even when given the option, not too many authors choose double-blinded peer-review for their manuscripts, ScienceInsider reports.

The Save the Redwoods League is teaming with researchers to sequence the genomes of the coast redwood and giant sequoia.

In PNAS this week: transcriptional read-through in stressed cells, genome stability role for the epigenetic regulator CTCF, and more.

Two researchers have found that behavioral genetic defenses in criminal cases don't tend to affect outcomes, according to Popular Science.